Prime Report: Oncology Medical Benefit Drugs Continue to Drive Trend
-
Nov 14, 2024
Medical benefit per-member per-month (PMPM) trend continued to increase last year in commercial, Medicare and Medicaid lines of business. That’s one of the findings from Prime Therapeutics LLC’s 14th annual Medical Pharmacy Trend Report, which also unsurprisingly revealed that oncology is the top category of PMPM spend in all three lines of business. And while biosimilars continue to pull share from their oncolytic reference drugs, next year may be the first year to see nononcology medical benefit biosimilars pick up share, pointed out an industry expert at a recent webinar.
Previously known as the Magellan Rx Management Medical Pharmacy Trend Report, the recently released report includes information on 2023 health plan paid claims data on provider-administered medical benefit drugs, which make up more than half of total drug spending in the U.S.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.